Evidence map›Paper›PMID 27279482›Full record

ArticleScientific reports2016

Inhibition of herpes simplex virus 1 gene expression and replication by RNase P-associated external guide sequences.

Jin Liu, Luyao Shao, Phong Trang, Zhu Yang, Michael Reeves, Xu Sun, Gia-Phong Vu, Yu Wang, Hongjian Li, Congyi Zheng and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. RNase P: Beyond Precursor tRNA Processing.Genomics, proteomics & bioinformatics · 2024
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Jin LiuState Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, Hubei 430072, China.
Luyao ShaoState Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, Hubei 430072, China.
Phong TrangSchool of Public Health, University of California, Berkeley, CA 94720, USA.
Zhu YangTaizhou Institute of Virology, Taizhou, Jiangsu 225300, China.
Michael ReevesSchool of Public Health, University of California, Berkeley, CA 94720, USA.
Xu SunCollege of Life Sciences, Jinan University, Guangzhou, Guangdong 510632, China.
Gia-Phong VuSchool of Public Health, University of California, Berkeley, CA 94720, USA.
Yu WangTaizhou Institute of Virology, Taizhou, Jiangsu 225300, China.
Hongjian LiCollege of Life Sciences, Jinan University, Guangzhou, Guangdong 510632, China.
Congyi ZhengState Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, Hubei 430072, China.
Sangwei LuSchool of Public Health, University of California, Berkeley, CA 94720, USA.
Fenyong LiuState Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, Hubei 430072, China.
University of California, Berkeley · USWuhan University · CNJinan University · CN

Funding

RIBOZYMES FOR STUDIES AND TREATMENT OF HCMV INFECTIONSR01AI041927 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI LIU, FENYONG · 1997 to 2012
$3.7M
Cytomegalovirus virulence in immunodeficient hostsR01AI050468 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI LIU, FENYONG · 2002 to 2013
$3.4M
Human cytomegalovirus chromatin modifications in oral infectionR01DE023935 · NIDCR · UNIVERSITY OF CALIFORNIA BERKELEY · PI LIU, FENYONG · 2013 to 2017
$2.3M
Small RNA therapeutics for AIDS-associated infectionR01DE014842 · NIDCR · UNIVERSITY OF CALIFORNIA BERKELEY · PI LIU, FENYONG · 2002 to 2010
$2.2M
Bacteria Based Agents for Therapy of AIDS Associated InfectionsR01AI091536 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI LU, SANGWEI · 2011 to 2014
$1.3M
NIAID NIH HHS R01 AI041927NIAID NIH HHS R01 AI050468NIAID NIH HHS R01 AI091536NIDCR NIH HHS R01 DE014842NIDCR NIH HHS R01 DE023935
6 · The paper itself

Abstract

An external guide sequence (EGS) is a RNA sequence which can interact with a target mRNA to form a tertiary structure like a pre-tRNA and recruit intracellular ribonuclease P (RNase P), a tRNA processing enzyme, to degrade target mRNA. Previously, an in vitro selection procedure has been used by us to engineer new EGSs that are more robust in inducing human RNase P to cleave their targeted mRNAs. In this study, we constructed EGSs from a variant to target the mRNA encoding herpes simplex virus 1 (HSV-1) major transcription regulator ICP4, which is essential for the expression of viral early and late genes and viral growth. The EGS variant induced human RNase P cleavage of ICP4 mRNA sequence 60 times better than the EGS generated from a natural pre-tRNA. A decrease of about 97% and 75% in the level of ICP4 gene expression and an inhibition of about 7,000- and 500-fold in viral growth were observed in HSV infected cells expressing the variant and the pre-tRNA-derived EGS, respectively. This study shows that engineered EGSs can inhibit HSV-1 gene expression and viral growth. Furthermore, these results demonstrate the potential for engineered EGS RNAs to be developed and used as anti-HSV therapeutics.

Indexed as

Virus ReplicationGene ExpressionGene Expression Regulation, ViralHeLa CellsHerpesvirus 1, HumanHumansImmediate-Early ProteinsInverted Repeat SequencesKineticsRibonuclease PRNA, MessengerRNA StabilityRNA, ViralViral Loadherpes simplex virus, type 1 protein ICP4Immediate-Early ProteinsRibonuclease PRNA, MessengerRNA, Viral

Identifiers

PMID27279482
PMCPMC4899697
OpenAlexW2411036010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.